Growth Metrics

Gilead Sciences (GILD) Other Non-Current Assets (2009 - 2026)

Gilead Sciences posted quarterly Other Non-Current Assets of $4.6 billion for Q1 2026, up 17.64% year-on-year from $3.9 billion in Q1 2025, and down 6.01% on a QoQ basis from $4.8 billion in Q4 2025.

Gilead Sciences (GILD) has 18 years of Other Non-Current Assets data on file, last reported at $4.6 billion in Q1 2026.

  • For the quarter ending Q1 2026, Other Non-Current Assets rose 17.64% year-over-year to $4.6 billion; the trailing twelve-month figure through Mar 2026 stood at $4.6 billion (up 17.64% YoY), and the FY2025 full-year result was $4.8 billion, up 28.55% from the prior year.
  • Other Non-Current Assets for Q1 2026 stood at $4.6 billion, down from $4.8 billion in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $5.5 billion in Q3 2024 and bottomed at $3.8 billion in Q4 2024.
  • The 5-year median for Other Non-Current Assets is $4.8 billion (2022), against an average of $4.7 billion.
  • The widest annual swing landed in 2024, when Other Non-Current Assets surged 30.81%; it then fell 25.39% in 2025.
  • A 5-year view of Other Non-Current Assets shows it stood at $4.8 billion in 2022, then declined by 0.17% to $4.8 billion in 2023, then declined by 21.35% to $3.8 billion in 2024, then grew by 28.55% to $4.8 billion in 2025, then fell by 6.01% to $4.6 billion in 2026.
  • The last three Other Non-Current Assets figures came in at $4.6 billion (Q1 2026), $4.8 billion (Q4 2025), and $4.9 billion (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Other Non-Current Assets (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - 200.00 Mn
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn 7.23 Bn
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn 14.11 Bn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn 10.54 Bn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn 19.81 Bn
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn 12.76 Bn
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn 4.55 Bn
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn 9.83 Bn
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn 6.08 Bn
10 Gsk 88.34 Bn 83.66 Bn - 2.86 Bn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 4.55 Bn
Dec 31, 2025 4.85 Bn
Sep 30, 2025 4.87 Bn
Jun 30, 2025 4.03 Bn
Mar 31, 2025 3.87 Bn
Dec 31, 2024 3.77 Bn
Sep 30, 2024 5.49 Bn
Jun 30, 2024 4.77 Bn
Mar 31, 2024 5.19 Bn
Dec 31, 2023 4.79 Bn
Sep 30, 2023 4.20 Bn
Jun 30, 2023 5.11 Bn
Mar 31, 2023 4.95 Bn
Dec 31, 2022 4.80 Bn
Sep 30, 2022 4.62 Bn
Jun 30, 2022 4.86 Bn
Mar 31, 2022 5.13 Bn
Dec 31, 2021 4.96 Bn
Sep 30, 2021 4.74 Bn
Jun 30, 2021 5.55 Bn
Mar 31, 2021 5.53 Bn
Dec 31, 2020 5.71 Bn
Sep 30, 2020 6.01 Bn
Jun 30, 2020 7.02 Bn
Mar 31, 2020 7.08 Bn
Dec 31, 2019 7.44 Bn
Sep 30, 2019 5.23 Bn
Jun 30, 2019 2.91 Bn
Mar 31, 2019 2.92 Bn
Dec 31, 2018 2.56 Bn
Sep 30, 2018 2.79 Bn
Jun 30, 2018 2.61 Bn
Mar 31, 2018 2.64 Bn
Dec 31, 2017 2.72 Bn
Sep 30, 2017 2.61 Bn
Jun 30, 2017 2.32 Bn
Mar 31, 2017 2.31 Bn
Dec 31, 2016 3.90 Bn
Sep 30, 2016 1.65 Bn
Jun 30, 2016 1.48 Bn
Mar 31, 2016 383.00 Mn
Dec 31, 2015 934.00 Mn
Sep 30, 2015 409.00 Mn
Jun 30, 2015 682.00 Mn
Mar 31, 2015 447.00 Mn
Dec 31, 2014 731.00 Mn
Sep 30, 2014 487.85 Mn
Jun 30, 2014 497.50 Mn
Mar 31, 2014 191.35 Mn
Dec 31, 2013 519.00 Mn
Sep 30, 2013 177.45 Mn
Jun 30, 2013 183.66 Mn
Mar 31, 2013 149.95 Mn
Dec 31, 2012 159.19 Mn
Sep 30, 2012 170.63 Mn
Jun 30, 2012 171.28 Mn
Mar 31, 2012 169.84 Mn
Dec 31, 2011 174.58 Mn
Sep 30, 2011 131.65 Mn
Jun 30, 2011 189.27 Mn
Mar 31, 2011 197.00 Mn
Dec 31, 2010 181.15 Mn
Sep 30, 2010 111.95 Mn
Mar 31, 2010 219.19 Mn
Dec 31, 2009 226.25 Mn
Sep 30, 2009 79.21 Mn
Jun 30, 2009 89.98 Mn